Edwards Lifesciences Co. (NYSE:EW - Get Free Report) Director Michael A. Mussallem sold 29,350 shares of the business's stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the sale, the director now owns 4,486 shares of the company's stock, valued at approximately $414,596.12. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Edwards Lifesciences Price Performance
EW opened at $91.22 on Friday. The firm has a market cap of $54.91 billion, a P/E ratio of 39.66, a PEG ratio of 4.61 and a beta of 1.05. The firm has a 50-day moving average of $87.93 and a 200 day moving average of $76.72. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm's revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.64 earnings per share. On average, research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current year.
Analyst Upgrades and Downgrades
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
A number of analysts have commented on EW shares. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Evercore ISI boosted their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an "in-line" rating in a research note on Thursday. Oppenheimer boosted their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a research note on Monday, March 18th. OTR Global upgraded shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $90.67.
Check Out Our Latest Stock Report on Edwards Lifesciences
Hedge Funds Weigh In On Edwards Lifesciences
Several institutional investors have recently added to or reduced their stakes in EW. Sequoia Financial Advisors LLC boosted its position in Edwards Lifesciences by 11.4% during the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company's stock worth $1,081,000 after purchasing an additional 941 shares during the period. Zions Bancorporation N.A. boosted its position in Edwards Lifesciences by 34.7% during the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company's stock worth $204,000 after purchasing an additional 448 shares during the period. Covestor Ltd boosted its position in Edwards Lifesciences by 18.2% during the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company's stock worth $144,000 after purchasing an additional 188 shares during the period. Mather Group LLC. boosted its position in Edwards Lifesciences by 53.5% during the first quarter. Mather Group LLC. now owns 7,182 shares of the medical research company's stock worth $846,000 after purchasing an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp boosted its position in Edwards Lifesciences by 3.1% during the first quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company's stock worth $77,173,000 after purchasing an additional 19,798 shares during the period. Institutional investors own 79.46% of the company's stock.
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
